Nuclear energy startup Oklo saw its stock rise after announcing it cleared two major regulatory hurdles for its first reactor. The company secured a key safety design approval from the U.S. Department of Energy (DOE) and its first-ever license from the Nuclear Regulatory Commission (NRC), signaling a critical shift from planning to construction, according to Sherwood News. These milestones are essential for its plan to complete the reactor by late 2027 or 2028.
What Regulatory Milestones Did Oklo Achieve?
Oklo is moving forward with its first advanced reactor, named Aurora, at the Idaho National Laboratory. The company announced it signed an “other transaction agreement” (OTA) with the Department of Energy, a mechanism the government uses to fast-track research and prototyping deals with private firms.In a more critical step, the DOE’s Idaho Operations Office approved the reactor's preliminary safety design review. This allows the project, which broke ground in September, to proceed to the next phase of construction. According to Barron's, the company is targeting a completion date of late 2027 or 2028 for the facility to begin producing commercial power.
Separately, the Nuclear Regulatory Commission issued a materials license to an Oklo subsidiary. This license permits the company to handle, process, and distribute isotopes, a core part of its future operations. "This is Oklo’s first NRC-issued license and supports the transition from design and planning to real-world execution and progress," the company said in a statement.
Securing government approvals is one challenge. But turning those permits into a profitable business is another, and Wall Street is watching the company's financials closely.
How Are Analysts Reacting?
Despite the regulatory progress, analysts remain cautious about Oklo's financial position. The company is pre-revenue and reported a wider-than-expected full-year loss. Concerns center on its increasing capital expenditure (capex) plans and ongoing cash burn. As of December 31, 2025, Oklo reported having approximately $1.4 billion in cash and marketable securities.
Analysts have adjusted their expectations, reflecting both the positive momentum on permits and the financial hurdles ahead. Needham & Co. noted that the projected $350–$450 million in capex for fiscal year 2026 came in above expectations and lowered its price target accordingly.
Here is a summary of recent analyst ratings and price targets:
Analyst Firm
Rating
Price Target
Barclays
Overweight
$82.00
Citi
Neutral/High Risk
$73.50
Needham & Co.
Buy
$73.00
The mixed reviews highlight the core tension for Oklo: it is successfully navigating a complex regulatory environment but must manage high costs and a long timeline before generating any revenue.








